> Scientific Publications

Fried I, Lossos A, BenAmi T, Dvir R, Toledano H, Ben Arush M, Postovski A, AbuKuidar A, Yalon M and Weintraub M. A phase 1/2 trial of the antibody pidilizumab (MDV9300) in pediatric diffuse intrinsic pontine glioma [abstract]. Neuro-Oncology 2016 Jun; 18: Suppl 3, iii48–iii77.

Efebera YA, Rosko AE, Hofmeister C, Benner J, Bakan C, Stamper K, et al. First interim results of a phase I/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed/refractory multiple myeloma [abstract]. Blood. 2015 Dec 4;126(23):1838. [Epub ahead of print]

Rosenblatt J, Avivi I, Binyamini N, Uhl L, Somaiya P, Stroopinsky D, et al. Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation is well tolerated, induces anti-tumor immunity and may lead to eradication of measureable disease [abstract]. Blood. 2015 Dec 3;126(23):4218. [Epub ahead of print]

Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20;31(33):4199-206.

Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem‑Yehudar R, Kufe D, Avigan D. PD‑1 blockade by CT‑011, anti‑PD‑1 antibody, enhances ex vivo T‑cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409‑18.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Raed Samara R, Rotem-Yehudar R, Cook L, and Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur. J. Immunol. 2011. 41: 2977–2986.

Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010 Sep 30;116(13):2286-94.

Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008 May 15;14(10):3044-51.

Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, et al. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine. 2005 May 9;23(25):3280-7.

Hardy B, Morgenstern S, Raiter A, Rodionov G, Fadaeev L, Niv Y. BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice. Cancer Lett. 2005 Nov 18;229(2):217-22.

Hardy B, Indjiia L, Rodionov G, Raiter A, Inbal A. Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. Int J Oncol. 2001 Nov;19(5):897-902.

Raiter A, Rodionov G, Novogrodsky A, Hardy B. CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation. Int Immunol. 2000 Nov;12(11):1623-8.

Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. A lymphocyte activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc Natl Acad Sci USA, 1997 May 27;94(11):5756-60.